| Revision as of 14:28, 19 December 2024 editMo18ekula (talk | contribs)260 editsmNo edit summary← Previous edit |
Revision as of 20:12, 19 December 2024 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,879 edits ce; templated citesNext edit → |
| Line 1: |
Line 1: |
|
|
{{cs1 config|name-list-style=vanc|display-authors=6}} |
|
{{Infobox drug |
|
{{Infobox drug |
|
| drug_name = Mcn 5707 |
|
| drug_name = Mcn 5707 |
| Line 58: |
Line 59: |
|
| StdInChIKey = KWMNBUDYCCTHHL-SJLPKXTDSA-N |
|
| StdInChIKey = KWMNBUDYCCTHHL-SJLPKXTDSA-N |
|
}} |
|
}} |
|
|
Mcn 5707 is a ] agent designated for the treatment of depression. It was developed by ] of ] (now Johnson & Johnson) in the 1980’s.<ref>{{cite journal | vauthors = Maryanoff BE, Shank RP, Gardocki JF | date = 1986 | title = McN-5707 and McN-5652-Z | journal = Drugs of the Future | volume = 11 | issue = 1 | pages = 18 | doi = 10.1358/dof.1986.011.01.51629 }}</ref><ref name="pmid6747993">{{cite journal | vauthors = Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR | title = Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin | journal = Journal of Medicinal Chemistry | volume = 27 | issue = 8 | pages = 943–6 | date = August 1984 | pmid = 6747993 | doi = 10.1021/jm00374a001 }}</ref> |
|
Mcn 5707 is a ] agent designated for the treatment of depression. It was developed by ] of ] (now Johnson & Johnson) in the 1980’s. |
|
|
|
|
|
|
The Ki numbers quoted (24b) are: DAT 35.9nM, NET: 1.9nM and SERT = 8.5nM. |
|
|
|
|
|
Ref:<ref> Maryanoff, B. E., Shank, R. P., Gardocki, J. F. (1986). "McN-5707 and McN-5652-Z". Drugs of the Future. 11 (1): 18. doi:10.1358/dof.1986.011.01.51629. </ref><ref> Maryanoff, BE; et al.; Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin. J Med Chem 1984, 27, 8, 943.</ref><ref>Bruce E. Maryanoff, US4719216 (1988 to Janssen Pharmaceuticals Inc).</ref> |
|
|
|
|
|
|
For related agents, see ], ], ], ] & ]. |
|
For related agents, see ], ], ], ] & ]. |
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
|
== References == |
|
== References == |
